License

Recorded: 2012-02-15 Received: 2012-02-15 Pages: 8

Assignor

MEDEXGEN CO., LTD.

Executed: 2012-01-12

Assignee

KOREA PRIME PHARM CO., LTD.

158-3, DAEIN-DONG, DONG-GU, GWANGJU, KRX, KOREA, REPUBLIC OF

Covered Properties (4)

Method of Improving Efficacy of Biological Response-Modifying Proteins and the Exemplary Muteins

Application: 12/499,710 →

Concatameric Immunoadhesion Molecule

Application: 11/739,288 →

Thrombopoietin Protein Variants

Application: 10/519,390 →

Tetravalent Etanercept

Application: 10/363,427 →